Targeted molecular therapies for ovarian cancer: An update and future perspectives (Review)

Oncology Reports

Volumn 28, Issue 2, 2012, Pages 395-408

  Shigetomi, Hiroshi ^a   Higashiura, Yumi ^a   Kajihara, Hirotaka ^a   Kobayashi, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Checkpoint kinase; Hepetocyte nuclear factor 1 ; Ovarian cancer; Poly (ADP ribose) polymerase; Targeted therapy

Indexed keywords

ABAGOVOMAB; AFLIBERCEPT; ANTINEOPLASTIC AGENT; BAY 86 5321; BEVACIZUMAB; CARBOPLATIN; CATUMAXOMAB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EOS 200 4; ERLOTINIB; FARLETUZUMAB; GANITUMAB; GEMCITABINE; IMATINIB; LENALIDOMIDE; MAB B43 13; MM 121; MMI 121; OREGOVOMAB; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PLACEBO; PLATINUM; SAR 256212; SORAFENIB; TOPOTECAN; TRASTUZUMAB; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLOCIXIMAB;

ADVANCED CANCER; ANEMIA; BLEEDING; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY CANCER; LEUKOPENIA; LOADING DRUG DOSE; MALIGNANT ASCITES; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; UTERINE TUBE CARCINOMA; UTERINE TUBE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS;

EID: 84863458937     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1833     Document Type: Review

References (70)

1. Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S and Morrison J: Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 9: CD007930, 2011.
2. Banerjee S and Kaye S: The role of targeted therapy in ovarian cancer. Eur J Cancer 47 (Suppl 3): S116-S130, 2011.
3. Oei AL, Sweep FC, Thomas CM, Boerman OC and Massuger LF: The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (Review). Int J Oncol 32: 1145-1157, 2008.
4. Reichert JM: Antibody-based therapeutics to watch in 2011. MAbs 3: 76-99, 2011.
5. Itamochi H: Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World J Biol Chem 1: 209-220, 2010.
6. Richardson DL, Backes FJ, Seamon LG, et al: Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol 111: 461-466, 2008.
7. Jurado JM, Sánchez A, Pajares B, Pérez E, Alonso L and Alba E: Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol 10: 583-586, 2008.
8. Perren TJ, Swart AM, Pfisterer J, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484-2496, 2011.
9. Köhne CH: How to integrate molecular targeted agents in the continuum of care. Ann Oncol 21 (Suppl 7): vii134-vii139, 2010.
10. Moroney JW, Sood AK and Coleman RL: Aflibercept in epithelial ovarian carcinoma. Future Oncol 5: 591-600, 2009.
11. Teng LS, Jin KT, He KF, Zhang J, Wang HH and Cao J: Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc 73: 449-456, 2010.
12. Colombo N, Mangili G, Mammoliti S, et al: A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol 125: 42-47, 2012.
13. Coleman RL, Duska LR, Ramirez PT, et al: Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 12: 1109-1117, 2011.
14. Neal J and Wakelee H: AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Curr Opin Mol Ther 12: 487-495, 2010.
15. Karlan BY, Oza AM, Richardson GE, et al: Randomized, double-blind, placebo-controlled phase II Study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30: 362-371, 2012.
16. Yarom N and Jonker DJ: The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med 11: 95-105, 2011.
17. Steffensen KD, Waldstrøm M, Jeppesen U, Jakobsen E, Brandslund I and Jakobsen A: The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer 17: 798-807, 2007. (Pubitemid 47063320)
18. Farley J, Fuchiuji S, Darcy KM, et al: Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol 113: 341-347, 2009.
19. Tang L and Zhao X: Polyclonal antitumor immunoglobulin may play a role in ovarian cancer adjuvant therapy. Med Hypotheses 76: 530-532, 2011.
20. Makhija S, Amler LC, Glenn D, et al: Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 28: 1215-1223, 2010.
21. Langdon SP, Faratian D, Nagumo Y, Mullen P and Harrison DJ: Pertuzumab for the treatment of ovarian cancer. Expert Opin Biol Ther 10: 1113-1120, 2010.
22. Sheng Q, Liu X, Fleming E, et al: An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17: 298-310, 2010.
23. Konner JA, Bell-McGuinn KM, Sabbatini P, et al: Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16: 5288-5295, 2010.
24. Berek J, Taylor P, McGuire W, Smith LM, Schultes B and Nicodemus CF: Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 27: 418-425, 2009.
25. Sabbatini P, Dupont J, Aghajanian C, et al: Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 12: 5503-5510, 2006. (Pubitemid 44497267)
26. Grisham RN, Berek J, Pfisterer J and Sabbatini P: Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy 3: 153-162, 2011.
27. Ruf P and Lindhofer H: Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98: 2526-2534, 2001.
28. Baumann K, Pfisterer J, Wimberger P, et al: Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol 123: 27-32, 2011.
29. Bell-McGuinn KM, Matthews CM, Ho SN, et al: A phase II, single-arm study of the anti-á5â1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121: 273-279, 2011.
30. Matei D, Sill MW, Lankes HA, et al: Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 29: 69-75, 2011.
31. Bodnar L, Górnas M and Szczylik C: Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecol Oncol 123: 33-36, 2011.
32. Ramasubbaiah R, Perkins SM, Schilder J, et al: Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol 123: 499-504, 2011.
33. Welch SA, Hirte HW, Elit L, et al: Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer 20: 787-793, 2010.
34. Pölcher M, Eckhardt M, Coch C, et al: Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 66: 203-207, 2010.
35. Eichbaum M, Mayer C, Eickhoff R, et al: The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer 11: 453, 2011.
36. Friedlander M, Hancock KC, Rischin D, et al: A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119: 32-37, 2010.
37. Patel BB, He YA, Li XM, et al: Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics 5: 137-149, 2008.
38. Santen RJ, Brodie H, Simpson ER, Siiteri PK and Brodie A: History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 30: 343-375, 2009.
39. Juretzka M, Hensley ML, Tew W, et al: A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. Eur J Gynaecol Oncol 29: 568-572, 2008.
40. Blank SV, Christos P, Curtin JP, et al: Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol 119: 451-456, 2010.
41. Nimeiri HS, Oza AM, Morgan RJ, et al: Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 110: 49-55, 2008.
42. Garcia AA, Sill MW, Lankes HA, et al: A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study. Gynecol Oncol 124: 569-574, 2012.
43. Kimball KJ, Numnum TM, Kirby TO, et al: A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol 111: 95-101, 2008.
44. Weroha SJ, Oberg AL, Ziegler KL, et al: Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol 122: 116-120, 2011.
45. Murphy M and Stordal B: Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resist Updat 14: 177-190, 2011.
46. Gnoni A, Marech I, Silvestris N, Vacca A and Lorusso V: Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets 12: 563-578, 2011.
47. Le XF, Mao W, Lu Z, Carter BZ and Bast RC Jr: Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 116: 4980-4990, 2010.
48. Oza AM, Elit L, Tsao MS, et al: Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 29: 3278-3285, 2011.
49. Behbakht K, Sill MW, Darcy KM, et al: Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 123: 19-26, 2011.
50. Temkin SM, Yamada SD and Fleming GF: A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 117: 473-476, 2010.
51. Kollmannsberger C, Hirte H, Siu LL, et al: Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Ann Oncol 23: 238-244, 2012.
52. Janku F, Wheler JJ, Westin SN, et al: PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30: 777-782, 2012.
53. Radosa MP, Häfner N, Camara O, et al: Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer. Int J Gynecol Cancer 21: 1399-1406, 2011.
54. Narod SA: BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 7: 702-707, 2010.
55. Javle M and Curtin NJ: The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 3: 257-267, 2011.
56. Lord CJ and Ashworth A: Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 8: 363-369, 2008.
57. Turner N, Tutt A and Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4: 814-819, 2004. (Pubitemid 39331153)
58. Penning TD: Small-molecule PARP modulators - current status and future therapeutic potential. Curr Opin Drug Discov Devel 13: 577-586, 2010.
59. Fong PC, Yap TA, Boss DS, et al: Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28: 2512-2519, 2010.
60. Gelmon KA, Tischkowitz M, Mackay H, et al: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12: 852-861, 2011.
61. Welch S, Hirte HW, Carey MS, et al: UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol 106: 305-310, 2007. (Pubitemid 47096653)
62. Morgan MA, Parsels LA, Zhao LP, et al: Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 70: 4972-4981,2010.
63. Kajihara H, Yamada Y, Kanayama S, et al: Clear cell carcinoma of the ovary: potential pathogenic mechanisms (Review). Oncol Rep 23: 1193-1203, 2010.
64. Yamada Y, Shigetomi H, Onogi A, et al: Redox-active iron-induced oxidative stress in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer 21: 1200-1207, 2011.
65. Smyth JF, Gourley C, Walker G, et al: Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 13: 3617-3622, 2007. (Pubitemid 46955124)
66. Fang F, Balch C, Schilder J, et al: A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 116: 4043-4053, 2010.
67. Modesitt SC, Sill M, Hoffman JS, Bender DP and Gynecologic Oncology Group: A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109: 182-186, 2008.
68. Tutt A, Robson M, Garber JE, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235-244, 2010.
69. Itamochi H, Yoshida T, Walker CL, et al: Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol 122: 641-647, 2011.
70. Vance S, Liu E, Zhao L, et al: Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle 10: 4321-4329, 2011.